Sukumar Nagendran sold $1.7M of TSHA
President and Head of R&D at Taysha Gene Therapies, Inc.. 370,172 shares at an average of $4.58, traded Nov 28, 2025, filed Dec 1, 2025.
Score components
- +20RolePresident
- +25Trade size$1.7M at market
- +10Share of holdings soldSold 33% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +24.2%, 3m +2.3%, 6m +34.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001665124-25-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 28, 2025 | MOption exercise Common Stock | +70,172 | $0.70 | $49k | 1,076,611 | Dec 1, 2025 |
| Nov 28, 2025 | MOption exercise Common Stock | +39,953 | $1.71 | $68k | 1,116,564 | Dec 1, 2025 |
| Nov 28, 2025 | SOpen-market sale Common Stock | -110,125 | $4.75 | $523k | 1,006,439 | Dec 1, 2025 |
| Dec 1, 2025 | MOption exercise Common Stock | +260,047 | $1.71 | $445k | 1,266,486 | Dec 1, 2025 |
| Dec 1, 2025 | SOpen-market sale Common Stock | -260,047 | $4.51 | $1.2M | 1,006,439 | Dec 1, 2025 |
| Nov 28, 2025 | MOption exercise Employee Stock Option (right to buy)derivative | -70,172 | $0.00 | $0 | 222,683 | Dec 1, 2025 |
| Nov 28, 2025 | MOption exercise Employee Stock Option (right to buy)derivative | -39,953 | $0.00 | $0 | 823,664 | Dec 1, 2025 |
| Dec 1, 2025 | MOption exercise Employee Stock Option (right to buy)derivative | -260,047 | $0.00 | $0 | 563,617 | Dec 1, 2025 |
Related signals
Other insiders at Taysha Gene Therapies, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $1.2M 200,000 shares | -18% | |
| 13Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $892k 200,000 shares | -15% | |
| 37Weak | Taysha Gene Therapies, Inc. | Kamran Alam CHIEF FINANCIAL OFFICER | $7,481 1,655 shares | -0% | |
| 55Moderate | Taysha Gene Therapies, Inc. | Kamran Alam CHIEF FINANCIAL OFFICER | $485k 102,817 shares | -7% | |
| 54Moderate | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $547k 116,050 shares | -8% | |
| 63Notable | Taysha Gene Therapies, Inc. | Sean P. Nolan Chief Executive Officer | $840k 178,101 shares | -6% | |
| 29Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $942k 200,000 shares | -17% | |
| 10Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $646k 200,000 shares | -17% | |
| 41Moderate | Taysha Gene Therapies, Inc. | Kamran Alam CHIEF FINANCIAL OFFICER | $155k 54,491 shares | -4% | |
| 39Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $163k 57,054 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.